Publicaciones científicas

Dendritic Cells in Cancer Immunology and Immunotherapy

28-feb-2024 | Revista: Cancers

Laura Hato  1 , Angel Vizcay  2   3 , Iñaki Eguren  2 , José L Pérez-Gracia  2 , Javier Rodríguez  2   3 , Jaime Gállego Pérez-Larraya  4 , Pablo Sarobe  3   5   6 , Susana Inogés  3   7 , Ascensión López Díaz de Cerio  3   7 , Marta Santisteban  2   3


Cancer immunotherapy modulates the immune system, overcomes immune escape and stimulates immune defenses against tumors. Dendritic cells (DCs) are professional promoters of immune responses against tumor antigens with the outstanding ability to coordinate the innate and adaptive immune systems. Evidence suggests that there is a decrease in both the number and function of DCs in cancer patients.

Therefore, they represent a strong scaffold for therapeutic interventions. DC vaccination (DCV) is safe, and the antitumoral responses induced are well established in solid tumors. Although the addition of checkpoint inhibitors (CPIs) to chemotherapy has provided new options in the treatment of cancer, they have shown no clinical benefit in immune desert tumors or in those tumors with dysfunctional or exhausted T-cells.

In this way, DC-based therapy has demonstrated the ability to modify the tumor microenvironment for immune enriched tumors and to potentiate systemic host immune responses as an active approach to treating cancer patients. Application of DCV in cancer seeks to obtain long-term antitumor responses through an improved T-cell priming by enhancing previous or generating de novo immune responses.

To date, DCV has induced immune responses in the peripheral blood of patients without a significant clinical impact on outcome. Thus, improvements in vaccines formulations, selection of patients based on biomarkers and combinations with other antitumoral therapies are needed to enhance patient survival.

In this work, we review the role of DCV in different solid tumors with their strengths and weaknesses, and we finally mention new trends to improve the efficacy of this immune strategy.

CITA DEL ARTÍCULO  Cancers (Basel). 2024 Feb 28;16(5):981.  doi: 10.3390/cancers16050981